Elite Diagnostic Limited (JMSE:ELITE)
Jamaica · Delayed Price · Currency is JMD 1.510
0.00 (0.00%)
At close: Mar 10, 2025
Ligand Pharmaceuticals Income Statement
Financials in millions JMD. Fiscal year is July - June.
Millions JMD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2017 - 2020 |
| 873 | 821.28 | 755.33 | 624.22 | 506.91 | 439.8 | Upgrade | |
Revenue Growth (YoY) | 13.87% | 8.73% | 21.00% | 23.14% | 15.26% | 8.63% | Upgrade |
Cost of Revenue | 277.88 | 278.13 | 277.27 | 223.58 | 200.5 | 177.54 | Upgrade |
Gross Profit | 595.12 | 543.16 | 478.06 | 400.64 | 306.4 | 262.26 | Upgrade |
Selling, General & Admin | 342.22 | 312.56 | 276.9 | 210.66 | 174.77 | 144.34 | Upgrade |
Operating Expenses | 501.66 | 447.79 | 413.35 | 318.19 | 276.83 | 232.52 | Upgrade |
Operating Income | 93.46 | 95.37 | 64.71 | 82.45 | 29.58 | 29.75 | Upgrade |
Interest Expense | -39.85 | -48.64 | -32.67 | -27.33 | -21.02 | -20.77 | Upgrade |
Interest & Investment Income | 0.09 | 0.09 | 0.1 | 0.01 | 0.09 | 0.04 | Upgrade |
Currency Exchange Gain (Loss) | 0.88 | -3.32 | -4.56 | -6.47 | -6.72 | -0.47 | Upgrade |
Other Non Operating Income (Expenses) | -14.2 | -14.15 | -14.2 | - | - | - | Upgrade |
Pretax Income | 40.39 | 29.35 | 13.39 | 48.66 | 1.93 | 8.55 | Upgrade |
Income Tax Expense | 3.67 | 3.19 | 0.04 | - | - | - | Upgrade |
Net Income | 36.72 | 26.16 | 13.35 | 48.66 | 1.93 | 8.55 | Upgrade |
Net Income to Common | 36.72 | 26.16 | 13.35 | 48.66 | 1.93 | 8.55 | Upgrade |
Net Income Growth | 431.99% | 95.90% | -72.56% | 2422.31% | -77.44% | -83.50% | Upgrade |
Shares Outstanding (Basic) | 353 | 353 | 353 | 353 | 353 | 353 | Upgrade |
Shares Outstanding (Diluted) | 353 | 353 | 353 | 353 | 353 | 353 | Upgrade |
EPS (Basic) | 0.10 | 0.07 | 0.04 | 0.14 | 0.01 | 0.02 | Upgrade |
EPS (Diluted) | 0.10 | 0.07 | 0.04 | 0.14 | 0.01 | 0.02 | Upgrade |
EPS Growth | 432.00% | 95.91% | -72.56% | 2422.72% | -77.45% | -83.50% | Upgrade |
Free Cash Flow | 141.49 | 92.29 | -25.87 | -127.87 | 38.8 | -22.52 | Upgrade |
Free Cash Flow Per Share | 0.40 | 0.26 | -0.07 | -0.36 | 0.11 | -0.06 | Upgrade |
Dividend Per Share | - | - | - | 0.020 | 0.090 | - | Upgrade |
Dividend Growth | - | - | - | -77.78% | - | - | Upgrade |
Gross Margin | 68.17% | 66.14% | 63.29% | 64.18% | 60.45% | 59.63% | Upgrade |
Operating Margin | 10.71% | 11.61% | 8.57% | 13.21% | 5.83% | 6.76% | Upgrade |
Profit Margin | 4.21% | 3.19% | 1.77% | 7.80% | 0.38% | 1.94% | Upgrade |
Free Cash Flow Margin | 16.21% | 11.24% | -3.43% | -20.48% | 7.65% | -5.12% | Upgrade |
EBITDA | 220.96 | 198.65 | 173.05 | 177.25 | 116.11 | 103.06 | Upgrade |
EBITDA Margin | 25.31% | 24.19% | 22.91% | 28.40% | 22.91% | 23.43% | Upgrade |
D&A For EBITDA | 127.5 | 103.29 | 108.33 | 94.8 | 86.53 | 73.31 | Upgrade |
EBIT | 93.46 | 95.37 | 64.71 | 82.45 | 29.58 | 29.75 | Upgrade |
EBIT Margin | 10.71% | 11.61% | 8.57% | 13.21% | 5.83% | 6.76% | Upgrade |
Effective Tax Rate | 9.08% | 10.88% | 0.26% | - | - | - | Upgrade |
Advertising Expenses | - | 5.23 | 9.61 | 5.9 | 4.06 | 2.26 | Upgrade |
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.